Bank of Montreal’s Revance Therapeutics, Inc. RVNC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-6,474
Closed -$57.8K 4433
2023
Q4
$57.8K Sell
6,474
-2,036
-24% -$16.7K ﹤0.01% 3523
2023
Q3
$153K Sell
8,510
-34,567
-80% -$665K ﹤0.01% 3156
2023
Q2
$1.27M Sell
43,077
-3,443
-7% -$107K ﹤0.01% 2054
2023
Q1
$1.52M Buy
+46,520
New +$1.45M ﹤0.01% 1821
2021
Q3
Sell
-19,385
Closed -$617K 3974
2021
Q2
$617K Sell
19,385
-1,768
-8% -$51K ﹤0.01% 2724
2021
Q1
$586K Sell
21,153
-9,381
-31% -$259K ﹤0.01% 2547
2020
Q4
$884K Buy
30,534
+6,830
+29% +$177K ﹤0.01% 2328
2020
Q3
$604K Sell
23,704
-1,414
-6% -$37.1K ﹤0.01% 2240
2020
Q2
$637K Buy
25,118
+4,704
+23% +$92.8K ﹤0.01% 2140
2020
Q1
$279K Buy
20,414
+246
+1% +$5.09K ﹤0.01% 2220
2019
Q4
$327K Buy
20,168
+10,142
+101% +$157K ﹤0.01% 2897
2019
Q3
$130K Sell
10,026
-275
-3% -$3.36K ﹤0.01% 3162
2019
Q2
$134K Buy
10,301
+7,059
+218% +$89K ﹤0.01% 3158
2019
Q1
$51K Sell
3,242
-223
-6% -$3.87K ﹤0.01% 3337
2018
Q4
$69K Buy
3,465
+238
+7% +$5.24K ﹤0.01% 3143
2018
Q3
$81K Buy
3,227
+2,994
+1,285% +$81.4K ﹤0.01% 3193
2018
Q2
$6K Buy
+233
New +$7K ﹤0.01% 4095
2016
Q1
Sell
-73
Closed -$2K 4435
2015
Q4
$2K Buy
+73
New +$2.53K ﹤0.01% 4009
2014
Q3
Sell
-170
Closed -$6K 4468
2014
Q2
$6K Buy
+170
New +$5.33K ﹤0.01% 4109

Other funds holding RVNC

Bank of Montreal's RVNC Position: Q1 2024 in Review

Bank of Montreal sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 6,474 shares — an estimated $57.8K sold.

Bank of Montreal first reported a position in RVNC in Q2 2014 and held it in 19 quarters. The position peaked at $1.52M in Q1 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Bank of Montreal reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Bank of Montreal sold 6,474 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $57.8K.
  • Bank of Montreal first reported a position in Revance Therapeutics, Inc. in Q2 2014 and held it in 19 quarters.
  • Bank of Montreal's Revance Therapeutics, Inc. position peaked at $1.52M in Q1 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Bank of Montreal's 13F filing for Q1 2024, filed 13 May 2024.